Search research articles
Contact Us
Filters
Showing results (21-30 of 43) with videos related to
Page
of 5
Sort By:
Cancer Genetics
|
October 27, 2012
MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
Neda Mosakhani, Leo Lahti, Ioana Borze, et al.
Plos One
|
November 25, 2020
Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing
Matilda Holm, Emma Andersson, Emerik Osterlund, et al.
International Journal of Molecular Sciences
|
April 13, 2023
Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
Kaisa Lehtomäki, Eetu Heervä, Pirkko-Liisa Kellokumpu-Lehtinen, et al.
Cancers
|
August 7, 2021
Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
Kaisa Lehtomäki, Harri Mustonen, Pirkko-Liisa Kellokumpu-Lehtinen, et al.
The Lancet. Gastroenterology & Hepatology
|
March 11, 2019
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
Stine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, et al.
Journal of Geriatric Oncology
|
September 20, 2023
The effect of BRAF<sup>V600E</sup> mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-study
Gabor Liposits, Stine B Winther, Jesper Ryg, et al.
Journal of Geriatric Oncology
|
December 9, 2022
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study
Gabor Liposits, Jesper Ryg, Halla Skuladottir, et al.
Journal of Clinical Medicine
|
October 14, 2022
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Gabor Liposits, Halla Skuladottir, Jesper Ryg, et al.
Plos One
|
December 14, 2020
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
Abir Salwa Ali, Seppo W Langer, Birgitte Federspiel, et al.
Scandinavian Journal of Gastroenterology
|
November 30, 2025
Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the Finnish RAXO study
Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 43) with videos related to
Sort By:
Page
of 5
Cancer Genetics
|
October 27, 2012
MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
Neda Mosakhani, Leo Lahti, Ioana Borze, et al.
Plos One
|
November 25, 2020
Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing
Matilda Holm, Emma Andersson, Emerik Osterlund, et al.
International Journal of Molecular Sciences
|
April 13, 2023
Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
Kaisa Lehtomäki, Eetu Heervä, Pirkko-Liisa Kellokumpu-Lehtinen, et al.
Cancers
|
August 7, 2021
Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
Kaisa Lehtomäki, Harri Mustonen, Pirkko-Liisa Kellokumpu-Lehtinen, et al.
The Lancet. Gastroenterology & Hepatology
|
March 11, 2019
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
Stine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, et al.
Journal of Geriatric Oncology
|
September 20, 2023
The effect of BRAF<sup>V600E</sup> mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-study
Gabor Liposits, Stine B Winther, Jesper Ryg, et al.
Journal of Geriatric Oncology
|
December 9, 2022
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study
Gabor Liposits, Jesper Ryg, Halla Skuladottir, et al.
Journal of Clinical Medicine
|
October 14, 2022
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Gabor Liposits, Halla Skuladottir, Jesper Ryg, et al.
Plos One
|
December 14, 2020
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
Abir Salwa Ali, Seppo W Langer, Birgitte Federspiel, et al.
Scandinavian Journal of Gastroenterology
|
November 30, 2025
Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the Finnish RAXO study
Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, et al.
Page
of 5